Armata Pharmaceuticals Inc - Asset Resilience Ratio
Armata Pharmaceuticals Inc (ARMP) has an Asset Resilience Ratio of 4.33% as of June 2000. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Armata Pharmaceuticals Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2017)
This chart shows how Armata Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Armata Pharmaceuticals Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Armata Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Armata Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.53 Million | 4.33% |
| Total Liquid Assets | $1.53 Million | 4.33% |
Asset Resilience Insights
- Limited Liquidity: Armata Pharmaceuticals Inc maintains only 4.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Armata Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Armata Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
ChemPartner PharmaTech Co Ltd
SHE:300149 |
Biotechnology | 1.67% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653 |
Biotechnology | 59.25% |
Annual Asset Resilience Ratio for Armata Pharmaceuticals Inc (1999–2017)
The table below shows the annual Asset Resilience Ratio data for Armata Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 86.65% | $9.65 Million | $11.14 Million | +64.02pp |
| 1999-12-31 | 22.63% | $3.10 Million | $13.70 Million | -- |
About Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudo… Read more